PureTech Health PLC Sponsored ADR PRTC 深 沪
已收盘 05-15 16:00:00 美东时间
17.39
-0.570
-3.17%
华盛通- 最 高17.7001
- 今 开17.70
- 成交量 5464股
- 最 低 17.39
- 昨 收 17.96
- 总市值 4.23亿
- 52周最高 19.95
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 14.50
- 委 比 -98.02%
- 总股本 2434.18万
- 历史最高 65.90
- 量 比 0.27
- 振 幅 1.73%
- 历史最低 13.30
- 每 手 1
- 风险率 1.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For April 29, 2026
Companies Reporting Before The Bell • Extreme Networks (NASDAQ:EXTR) is likely ...
04-29 19:11
PureTech Health to release annual results, hosts conference call and webcast
PureTech Health to release annual results, hosts conference call and webcast PureTech Health will publish Annual Report and Accounts with financial results for year ended Dec. 31, 2025 on April 29, 2026. Results presentation with conference call scheduled for 9:00 a.m. EDT / 2:00 p.m. BST on April 2
04-13 14:11
PureTech's Founded Entity, Seaport Therapeutics, Announces Topline Data From Portions Of Ongoing Phase 1 Proof-Of-Concept Clinical Trial Evaluating GlyphAgo
PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded
04-02 19:19
PureTech Health's Seaport Therapeutics Announces Publication Of First-In-Human Clinical And Preclinical Data For GlyphAllo In Science Translational Medicine
PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded
03-26 02:09
PureTech-Backed Seaport Validates Oral Prodrug Platform With Human Data on Depression Candidate
PureTech Health ( ($GB:PRTC) ) has issued an announcement. PureTech Health’s fo...
03-26 02:07
CAMP4 Appoints Michael MacLean to its Board of Directors
CAMP4 Therapeutics announced the appointment of Michael MacLean to its Board of Directors. With over 35 years of financial and operational leadership in biotechnology, MacLean brings extensive experience in growing innovative biotech companies. His expertise will support CAMP4 as it advances its CMP-002 program toward a Phase 1/2 clinical trial for SYNGAP1-related disorder, for which there are currently no approved treatments. MacLean previously ...
03-24 11:00
PureTech Health to Present at Leerink Partners Global Healthcare Conference
PureTech Health to Present at Leerink Partners Global Healthcare Conference PureTech Health plc said CEO Robert Lyne and Co-founder and President Eric Elenko will take part in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20am EDT, with a we
02-25 15:00
PureTech’s Deupirfenidone Wins U.S. and EU Orphan Status for Idiopathic Pulmonary Fibrosis
PureTech Health ( ($GB:PRTC) ) has issued an announcement. PureTech Health’s Fo...
02-20 01:17
PureTech names Robert Lyne as CEO
PureTech Health plc (PRTC) has appointed Robert Lyne as Chief Executive Officer and as a member of the Board of Directors, effective immediately. Lyne has served as interim CEO since July 2025 and joi...
2025-12-18 18:18
